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Abstract: BACKGROUND: Nephroblastoma and neuroblastoma belong to the most common abdominal
malignancies in childhood. Similarities in the initial presentation may provide difficulties in distinguishing
between these two entities, especially if unusual variations to prevalent patterns of disease manifestation
occur. Because of the risk of tumor rupture, European protocols do not require biopsy for diagnosis, which
leads to misdiagnosis in some cases. CASE PRESENTATION: We report on a 4½-year-old girl with a
renal tumor displaying radiological and laboratory characteristics supporting the diagnosis of nephroblas-
toma. Imaging studies showed tumor extension into the inferior vena cava and bilateral lung metastases
while urine catecholamines and MIBG-scintigraphy were negative. Preoperative chemotherapy with vin-
cristine, actinomycine D and adriamycin according to the SIOP2001/GPOH protocol for the treatment
of nephroblastoma was initiated and followed by surgical tumor resection. Histopathology revealed an
undifferentiated tumor with expression of neuronal markers, suggestive of neuroblastoma. MYCN ampli-
fication could not be detected. DNA-microarray analysis was performed using Affymetrix genechip human
genome U133 plus 2.0 and artificial neural network analysis. Results were confirmed by multiplex RT-
PCR. RESULTS: Principal component analysis using 84 genes showed that the patient sample was clearly
clustering with neuroblastoma tumors. This was confirmed by hierarchical clustering of the multiplex
RT-PCR data. The patient underwent treatment for high-risk neuroblastoma comprising chemotherapy
including cisplatin, etoposide, vindesine, dacarbacine, ifosfamide, vincristine, adriamycine and autolo-
gous stem cell transplantation followed by maintenance therapy with 13-cis retinoic acid (GPOH NB2004
High Risk Trial Protocol) and is in complete long-term remission. CONCLUSION: The use of gene ex-
pression profiling in an individual patient strongly contributed to clarification in a diagnostic dilemma
which finally led to a change of diagnosis from nephroblastoma to neuroblastoma. This case underlines
the importance of gene-expression profiling in the correct diagnosis of childhood neoplasms with atypical
presentation to ensure that adequate treatment regimens can be applied.
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Case report: value of gene expression 
profiling in the diagnosis of atypical 
neuroblastoma
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Abstract 
Background: Nephroblastoma and neuroblastoma belong to the most common abdominal malignancies in child-
hood. Similarities in the initial presentation may provide difficulties in distinguishing between these two entities, 
especially if unusual variations to prevalent patterns of disease manifestation occur. Because of the risk of tumor 
rupture, European protocols do not require biopsy for diagnosis, which leads to misdiagnosis in some cases.
Case presentation: We report on a 4½-year-old girl with a renal tumor displaying radiological and laboratory char-
acteristics supporting the diagnosis of nephroblastoma. Imaging studies showed tumor extension into the inferior 
vena cava and bilateral lung metastases while urine catecholamines and MIBG-scintigraphy were negative. Preopera-
tive chemotherapy with vincristine, actinomycine D and adriamycin according to the SIOP2001/GPOH protocol for 
the treatment of nephroblastoma was initiated and followed by surgical tumor resection. Histopathology revealed an 
undifferentiated tumor with expression of neuronal markers, suggestive of neuroblastoma. MYCN amplification could 
not be detected. DNA-microarray analysis was performed using Affymetrix genechip human genome U133 plus 2.0 
and artificial neural network analysis. Results were confirmed by multiplex RT-PCR.
Results: Principal component analysis using 84 genes showed that the patient sample was clearly clustering with 
neuroblastoma tumors. This was confirmed by hierarchical clustering of the multiplex RT-PCR data. The patient under-
went treatment for high-risk neuroblastoma comprising chemotherapy including cisplatin, etoposide, vindesine, 
dacarbacine, ifosfamide, vincristine, adriamycine and autologous stem cell transplantation followed by maintenance 
therapy with 13-cis retinoic acid (GPOH NB2004 High Risk Trial Protocol) and is in complete long-term remission.
Conclusion: The use of gene expression profiling in an individual patient strongly contributed to clarification in a 
diagnostic dilemma which finally led to a change of diagnosis from nephroblastoma to neuroblastoma. This case 
underlines the importance of gene-expression profiling in the correct diagnosis of childhood neoplasms with atypical 
presentation to ensure that adequate treatment regimens can be applied.
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Background
Neuroblastoma and nephroblastoma belong to the most 
common malignant solid tumors in childhood. In both 
cases children might present with a distended abdomen. 
Although there is a considerable overlap of symptoms 
in the initial presentation such as abdominal distension, 
loss of appetite, nausea or hypertension, children with 
nephroblastoma usually are in a better clinical condition 
and are slightly older with a peak incidence of 2–3 years 
[1]. A palpable, painless abdominal mass may be the 
only symptom present. In contrast, as neuroblastoma 
is metastasized in almost 50% at initial diagnosis, these 
children experience symptoms such as fever and anemia 
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related to pancytopenia due to bone marrow involvement 
as well as weight loss and pain more frequently. Never-
theless, in some cases it may be difficult to distinguish 
neuroblastoma from nephroblastoma with standard 
diagnostic procedures but this is crucial with regard to 
optimal therapeutical management of these tumors [2, 3]. 
We describe a 4½ year old girl with neuroblastoma mis-
diagnosed as nephroblastoma based on the constellation 
of radiological and laboratory findings. Gene expression 
profiling and multiplex RT-PCR strongly supported the 
final diagnosis of neuroblastoma, underlining the impor-
tance of including molecular techniques in the diagnosis 
of childhood neoplasms with atypical presentation.
Case presentation
A 4½-year old girl presented with an abdominal mass and 
a 6-week-history of weight loss, decreased appetite and 
subsequent development of fever and abdominal pain. 
Physical examination and vital signs revealed no further 
pathological findings except of pallor, a reduced nutri-
tional status and a slightly elevated temperature. Abnor-
mal laboratory parameters indicative of a tumorous or 
inflammatory process are presented in Table  1. Urine 
catecholamines (homovanillic acid, vanillylmandelic 
acid) were not elevated. Abdominal magnetic resonance 
imaging (MRI) demonstrated an 8.8 ×  7.9 ×  9.4 cm ret-
roperitoneal mass located at the superior pole of the left 
kidney with the tumor capsule passing into the renal cap-
sule despite a non-infiltrative growth-pattern as shown 
in Fig. 1a (coronal image; marked by triangle). No vascu-
lar encasement or calcification was seen, but the tumor 
extended into the left renal vein (Fig. 1b, transversal image; 
marked by  arrow) and the inferior vena cava (Fig.  1a, 
arrow; Fig 1b, asterisk). Except of enlargement of ipsilateral 
lymph nodes up to 9 mm no other tumor manifestations 
within the abdomen were seen. Chest X-ray and echocar-
diogram were normal, but chest computed tomography 
(CT) identified several bilateral pulmonary lesions strongly 
suggestive of metastases, the largest measuring 6 × 4 mm 
in the medial segment of the middle lobe (Fig. 1c; marked 
by reverse triangle and arrow). Further lesions were seen 
in the posterior segment of the right superior lobe and 
in the dorsobasal segment of the left inferior lobe. Both 
inferior lobe arteries showed evidence for an occlusion 
by either a thrombus or particles of the intracaval tumor 
cone (Fig.  1d; marked by arrow). Meta-iodobenzylguan-
idine scan was negative as were bone scan and cranial 
MRI. Based on the imaging and laboratory findings the 
tumor was suspected to be a nephroblastoma and a 
biopsy omitted due to the presumed risk of tumor rup-
ture. Preoperative chemotherapy over 6  weeks according 
to the SIOP2001/GPOH-protocol with weekly intravenous 
administration of vincristine (1.5  mg/m2), actinomycine 
D (45  µg/m2) and adriamycine (50  mg/m2) was initiated, 
accompanied by continuous intravenous anticoagula-
tion with unfractionated heparin (100  IU/kg/24  h) with 
respect to intravasal tumor manifestation. As abdomi-
nal MRI after 2  weeks of treatment displayed a constant 
renal tumor size but an expansion of the IVC thrombus 
the anticoagulation regime was changed to subcutaneous 
low-molecular-weight heparin twice daily (1 mg/kg/24 h, 
then escalated to 1.5 mg/kg/24 h aiming at factor anti-Xa-
levels of 0.4–0.8 μmol/l). After 4 weeks of chemotherapy, 
MRI scans showed a slight regression of both the primary 
tumor mass and the IVC thrombus. After completion of 
6  weeks of preoperative chemotherapy, the pulmonary 
metastases and the emboli in the inferior lobe arteries 
had regressed on chest CT. Radical tumor-nephrectomy, 
extraction of the caval thrombus and regional staging-
lymphadenectomy were performed without major com-
plications. Histopathology revealed clustering small tumor 
cells, partially arranged in pseudorosettes with focal calci-
fications, invading the left kidney. Immunohistochemistry 
was positive for synaptophysin, a specific marker of neu-
ronal and neuroendocrine tumors and VMAT2, expressed 
in the CNS and sympathetic postganglionic neurons 
[Fig.  2a: expression of synaptophysin (400×); Fig.  2b: 
expression of VMAT (400×)]. PAN-cytokeratin and 
WT1, two major markers for nephroblastoma were nega-
tive as was desmin, a mesenchymal marker which can be 
positive in blastema-predominant nephroblastoma. These 
results further supported the diagnosis of undifferenti-
ated neuroblastoma. The MYCN gene which is the most 
relevant genetic biomarker in neuroblastoma predicting 
poor prognosis was not amplified in this specimen. In 
order to substantiate the diagnosis gene-expression profil-
ing and multiplex RT-PCR were done. Comparison of the 
gene expression profile using Affymetrix genechip human 
genome U133 plus 2.0 and artificial neural network (ANN) 
analysis of the patient’s sample with 36 tumor samples 
(12 rhabdomyosarcoma/RMS, 6 Ewing’s sarcoma/EWS, 14 
neuroblastoma/NB and 4 Wilms’-Tumor/WT specimen) 
revealed that the patient sample (test as grey) was closely 
Table 1 Abnormal laboratory values at  initial admission 
of the patient
Test Result Reference range Units
LDH 670 104–311 U/l
Ferritin 146 12–60 ng/ml
NSE 260.2 <17 µg/l
C-reactive proteine 65 ≤5 mg/l
D-dimers 422 ≤130 µg/l
Hemoglobin 10.4 11.0–15.0 g/dl
MCV 71 75–87 fl
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Fig. 1 MRI abdomen at initial diagnosis (T2-weighted images). a (Coronal). Left-sided abdominal mass (triangle) arising from the upper pole of the 
left kidney and tumor thrombus in the vena cava inferior (arrow). b (Transversal). Main tumor formation (triangle) and tumor cone in the left vena 
renalis (arrow) extending to the vena cava inferior (asterisk). Computed tomography scan of the lungs. c The arrows indicate the presence of lung 
metastases in the middle lobe (reverse triangle) and right inferior lobe close to the pulmonary fissure (arrow). d Embolic occlusion (arrow) of the left 
inferior lobe artery by either a thrombus or tumor
Fig. 2 Immunohistochemistry of the primary tumor. a Expression of synaptophysin (×400). b Expression of VMAT (×400)
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clustering with neuroblastoma (Fig.  3a; Additional file  1: 
Table S1). Hierarchical clustering of 10 samples (1 patient 
test sample, 3 RMSs, 3 NBs and 3 WTs) using a subset of 
23 genes out of a previously established panel of 39 genes 
to distinguish small round blue cell tumors confirmed 
by multiplex RT-PCR showed that the patients’ sample 
was clustering with neuroblastoma tumors [4]. A pseu-
docolored representation of z-scored  log2 ratio is shown 
(Fig. 3b). At that time the NSE had decreased to 20.2 μg/l 
(normal <17 μg/l), urine and serum catecholamines were 
still undetectable. Bone marrow aspiration and biopsy did 
not show any malignant cells. The following antineoplastic 
treatment comprised 6 cycles with alternating i.v. admin-
istration of either cisplatin/etoposide/vindesine or dacar-
bacine/ifosfamide/vincristine/adriamycin according to the 
GPOH NB2004 High Risk Trial Protocol. Intensification 
by high-dose, myeloablative chemotherapy with melpha-
lan/carboplatin/etoposide and autologous stem cell rescue 
and a maintenance therapy with 13-cis retinoic acid p.o. 
over 10 months followed. Neither laboratory nor imaging 
investigations have been indicative of a tumor recurrence 
since and the child is well more than 4 years after complet-
ing treatment. Timeline summarizing patient management 
according to CARE Guidelines is provided in Additional 
file 2.   
Conclusion
Neuroblastoma and nephroblastoma both belong to the 
family of embryonic tumors and are the most important 
differential diagnoses to consider in malignant abdominal 
childhood tumors. European treatment protocols favour 
the administration of neoadjuvant chemotherapy in the 
management of nephroblastoma due to the substantial 
risk of tumor rupture during biopsy. A histology-proven 
diagnosis will generally not be available until several 
weeks after the start of antineoplastic treatment. The pre-
histological differentiation of retroperitoneal tumors by 
radiological assessment based on certain diagnostic cri-
teria (e.g. calcifications, vessel encasement, cysts) there-
fore plays a crucial role with regard to the management 
of further diagnostic procedures, operative treatment 
and chemotherapy. However, a marginal risk for misdiag-
nosing these patients on the basis of radiological imag-
ing remains, especially in tumors that are located at the 
upper pole of the kidneys.
A retrospective analysis of 1609 patients registered 
in German neuroblastoma trials showed that 1.8% had 
been treated preoperatively as nephroblastomas [3]. 
Importantly, these patients have an inferior 5-year-EFS 
compared to patients treated according to neuroblas-
toma protocols from diagnosis on (0.40 vs. 0.64). These 
results especially held true for the subgroup of stage III 
patients (5-year EFS 0.27 vs. 0.68) whereas in the stage 
IV group the outcome was similarly dismal (5-year EFS 
0.25 vs. 0.31). The inferior outcome was attributed to the 
observed unfavourable biology of these tumors rather 
than to the fact that appropriate neuroblastoma treat-
ment was not primarily given.
In our case clear imaging findings indicative of neuro-
blastoma were absent but tumor expansion to the inferior 
Fig. 3 Gene expression profiling of the test patient tumor. a Loading plot of top three principal components of the 37 tumor samples (1 test 
patient sample, 12 RMS, 6 EWS, 14 NB and 4 WT) using 84 genes shows that the patient sample (test as grey) is closely clustering with NB. Affymetrix 
genechip human genome U133 plus 2.0 genechip is used to generate the data. RMS is depicted as red circles, EWS as green, NB as blue and WT as 
yellow. b Hierarchical clustering of 10 samples (1 test patient sample, 3 RMSs, 3 NBs and 3 WTs) and a subset of 23 genes out of a panel of 39 genes 
known to be differentially expressed in SRBCT using multiplex RT-PCR assay data shows that the test sample is clustering with NB. Each row repre-
sents a sample, and each column a gene. A pseudocolored representation of z-scored  log2 ratio is shown
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vena cava was seen. So far, only few patients have been 
described in the English literature, reflecting the sparsity 
of this form of neuroblastoma extension [5–7]. In con-
trast, 4–10% of nephroblastoma patients show evidence 
for an intracaval thrombus [8]. Treatment recommen-
dations include preoperative chemotherapy to induce 
regression of the tumor thrombus as reported in the 
majority of patients [9, 10].
Next to locoregional lymph nodes the organ most 
frequently involved by metastatic Wilms’ tumor is the 
lung. Our patient presented with bilateral pulmonary 
metastases, putting further weight on the diagnosis of a 
nephroblastoma. In contrast, although more than 50% of 
neuroblastoma patients have widespread disease at diag-
nosis, lung metastases are rather uncommon. In a large 
cohort of patients with stage IV neuroblastoma from 
the International Neuroblastoma Risk group database 
(n =  2808) the incidence of lung metastases at diagno-
sis was 3.6%. Patients with lung manifestation rather 
had prognostically relevant LDH elevation and MYCN-
amplification compared to the group of stage IV patients 
without pulmonary metastases (82.1% vs. 67% and 53.9% 
vs. 29.1%, respectively) [11].
In more than 90% of neuroblastoma patients either 
homovanillic acid or vanillylmandelic acid are elevated 
[12] and MIBG-scan is positive in 90–95% of patients 
[11]. Neuroblastoma patients preoperatively misdiag-
nosed as nephroblastoma are more likely to present with 
normal catecholamine metabolites (39% vs. 80%) and 
less likely to have a positive MIBG scintigraphy (71% vs. 
89%) in contrast to the group of neuroblastoma patients 
that were initially correctly diagnosed and treated [3]. 
Contrasting our case, an inverse correlation of catecho-
lamine levels and amplification of the MYCN protoonco-
gene has been described, showing that MYCN-positive 
tumors have rather low urinary VMA and HVA despite 
a comparably larger tumor volume [13, 14]. Interestingly, 
a mini case series by Gaetan et al. describes three neuro-
blastoma patients with intracaval tumor thrombus two of 
which had a similar constellation of both MYCN negativ-
ity and absence of elevated urine catecholamines [7].
Histopathology revealed clustering small tumor cells, 
partially arranged in pseudorosettes with focal calcifica-
tion present. No definite conjunction with the renal tis-
sue could be seen. Immunohistochemistry in our case 
stained clearly positive for synaptophysin (Fig.  2a) and 
vesicular monoamine transporter type 2 (VMAT2) 
whereas markers typically found in the majority of 
nephroblastomas were absent (Fig.  2b) [15, 16]. These 
findings were consistent with the diagnosis of undiffer-
entiated neuroblastoma, which represents the rarest of 
three categories that neuroblastomas are classified into 
according to the Shimada classification. In a large series 
of 3501 newly enrolled patients in the COG Neuroblas-
toma studies undifferentiated neuroblastoma accounted 
for 4.5% and frequently associated with poor prognosis 
biomarkers such as advanced disease or MYCN amplifi-
cation [17, 18]. However, Wilms’ tumors containing focal 
neural elements have been sporadically described in the 
literature with ganglion cells being the most prevalent 
neural element [19, 20]. Hussong et al. report on a famil-
ial series of four nephroblastomas all displaying histologic 
and immunohistochemical characteristics of focal neural 
differentiation, i.e. rosette formation and ganglion cells 
as wells as positive immunoreactivity for chromogranin, 
synaptophysin, NSE and vimentin. We therefore could 
not formally rule out the possibility of a nephroblastoma 
with heterologous cellular differentiation in our patient. 
MYCN was not amplified to serve as an important crite-
rion of distinction between neuro- and nephroblastoma. 
From the clinical point of view, after having completed 
the 6-week neoadjuvant chemotherapy, slight tumor 
regression was observed in the primary tumor as well as 
in the metastatic sites. On the one hand this might have 
been due to tumor heterogeneity containing responding 
and resistant cellular compartments but also to the fact 
that two of the three drugs given (vincristine and adria-
mycine) are also part of neuroblastoma treatment.
To accurately discriminate between tumors of similar 
histological appearance but different origin, biology and 
clinical behaviour is an ongoing research topic. In the 
field of SRBCT and the overlap of nephroblastoma and 
neuroblastoma two recent reports propose immunohisto-
chemical markers, cyclin D1 and PHOX2B, to be reliable 
for distinction of neuroblastoma from other malignancies 
[21, 22]. Different autoantibody signatures obtained from 
peripheral blood were detected with high sensitivity and 
specificity in untreated nephroblastoma and neuroblas-
toma patients, making this approach particularly interest-
ing in the absence of histological samples [23]. In the case 
described in this study previous establishment of diagnos-
tic signatures to distinguish SRBCT by gene expression 
analysis and a multiplex RT-PCR assay, the latter being 
extended for Wilms’ specific genes, allowed analysis of 
the patients’ tumor [24]. All results clearly showed that 
the patient sample clustered with neuroblastoma, further 
undermining the correct diagnostic reclassification and 
therapeutic restratification which led to a long-term com-
plete remission in a high-risk neuroblastoma patient.
In summary, we present the clinical case of a patient 
with a renal tumor in whom conventional diagnostic pro-
cedures could not reliably differentiate between neuro-
blastoma and nephroblastoma. We conclude that genetic 
molecular approaches can be a valuable and precise sup-
plemental tool for making the right diagnosis and insti-
tuting correct therapeutic management.
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